Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Adipokine signaling pathway (also called adipocytokine signaling pathway) refers to a complex network of signaling events initiated by adipokines—hormonal and cytokine-like molecules secreted by adipose tissue[1][3][6][9]. These pathways centrally regulate energy homeostasis, lipid metabolism, insulin sensitivity, inflammation, and immune function[3][4][6]. Key adipokines include adiponectin, leptin, resistin, and others. The pathway involves multiple signal mediators, such as AMP-activated protein kinase (AMPK), peroxisome proliferator-activated receptors (PPARs), Janus kinases/signal transducers and activators of transcription (JAK/STAT), PI3K/Akt, and others[1][2][6][7]. Disruption or dysregulation of adipokine signaling is linked to obesity, type 2 diabetes, metabolic syndrome, cardiovascular diseases, osteoarthritis, and autoimmune conditions[6][7][8]. However, the adipokine signaling pathway is not a single molecular target, receptor, or protein; it encompasses many different cellular components, ligands, receptors (such as AdipoR1, AdipoR2 for adiponectin; leptin receptor for leptin), and downstream molecules[2][3][6]. As such, it is not referred to as a therapeutic target in the sense of a single molecule (receptor, enzyme, transporter) suitable for direct drug targeting; instead, individual pathway components (e.g., adiponectin receptor 1, leptin receptor) may be considered targets[2][5]. It would be necessary to specify a particular component within this pathway (such as “adiponectin receptor 1” or “leptin receptor”) to meet the criteria for a canonical therapeutic target. There are no official abbreviations, molecular classifications, drug lists, or biomarker details that can be assigned to the “adipokine signaling pathway” as a whole. For structured data, focus on individual pathway members (e.g., AdipoR1, AdipoR2, leptin receptor) rather than the pathway aggregate. Correction: - "Adipokine signaling pathway" is not a specific target molecule, protein, or receptor but a pathway comprising many such individual entities. - For curation or database purposes, this entry should be flagged as non-compliant with requirements for a target entry. A more appropriate target would be, for example, “Adiponectin receptor 1 (AdipoR1)” or “Leptin receptor.”
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Adipokine signaling pathway.